Auristatin antibody drug conjugate physical instability and the role of drug payload.

The conjugation of hydrophobic cytotoxic agents such as monomethyl auristatin E (MMAE) to the interchain sulfhydryl groups of monoclonal antibodies (Mabs) through a protease-labile linker generates a heterogeneous drug load distribution. The conjugation process can generate high-drug-load species that can affect the physical stability of antibody-drug conjugates (ADCs). In this study, the mechanism of physical instability of ADCs was investigated by formulating the ADC pool as well as isolated drug load species in high and low ionic strength buffers to understand the effect of ionic strength on the stability of drug-conjugated Mabs. The results showed that the presence of high ionic strength buffer led to time-dependent aggregate and fragment formation of ADCs, predominantly ADCs with high-drug-load species under stress conditions. In addition, differential scanning calorimetry (DSC) results confirmed that there is a direct correlation between thermal unfolding and drug payload and that specific changes in the DSC thermogram profiles can be assigned to modifications by MMAE.

[1]  Peter D. Senter,et al.  Development of potent monoclonal antibody auristatin conjugates for cancer therapy , 2003 .

[2]  Aditya A Wakankar,et al.  Analytical methods for physicochemical characterization of antibody drug conjugates , 2011, mAbs.

[3]  Heather Flores,et al.  Investigation into temperature-induced aggregation of an antibody drug conjugate. , 2013, Bioconjugate chemistry.

[4]  Fred Jacobson,et al.  Protein aggregation and bioprocessing , 2006, The AAPS Journal.

[5]  Igor V. Tetko,et al.  Virtual Computational Chemistry Laboratory – Design and Description , 2005, J. Comput. Aided Mol. Des..

[6]  I. Hollander,et al.  Selection of reaction additives used in the preparation of monomeric antibody-calicheamicin conjugates. , 2008, Bioconjugate chemistry.

[7]  Bernhardt L Trout,et al.  Prediction of aggregation prone regions of therapeutic proteins. , 2010, The journal of physical chemistry. B.

[8]  P. Trail,et al.  Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains. , 2002, Journal of medicinal chemistry.

[9]  Y. Oki,et al.  Brentuximab vedotin in systemic T-cell lymphoma , 2012, Expert opinion on biological therapy.

[10]  Randall J Mrsny,et al.  Formulation and delivery issues for monoclonal antibody therapeutics. , 2006, Advanced drug delivery reviews.

[11]  Gopi Shankar,et al.  A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs , 2007, Nature Biotechnology.

[12]  P. Plotz,et al.  The specificity of uptake of model immune complexes and other protein aggregates by the murine reticuloendothelial system. , 1980, Journal of immunology.

[13]  Aditya A Wakankar,et al.  Physicochemical stability of the antibody-drug conjugate Trastuzumab-DM1: changes due to modification and conjugation processes. , 2010, Bioconjugate chemistry.

[14]  Paul Polakis,et al.  Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index , 2008, Nature Biotechnology.

[15]  T. Ueda,et al.  Effect of buffer species on the unfolding and the aggregation of humanized IgG. , 2007, Journal of biochemistry.

[16]  P. Trail,et al.  Monoclonal antibody conjugates of doxorubicin prepared with branched linkers: A novel method for increasing the potency of doxorubicin immunoconjugates. , 1999, Bioconjugate chemistry.

[17]  P. Burke,et al.  A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. , 2013, Bioconjugate chemistry.

[18]  Brian M. Murphy,et al.  Stability of Protein Pharmaceuticals: An Update , 2010, Pharmaceutical Research.

[19]  Uma Yasothan,et al.  Brentuximab vedotin , 2022, Nature Reviews Drug Discovery.

[20]  A. Vermeer,et al.  The thermal stability of immunoglobulin: unfolding and aggregation of a multi-domain protein. , 2000, Biophysical journal.

[21]  Damon L. Meyer,et al.  Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate , 2004, Clinical Cancer Research.

[22]  Xinxia Peng,et al.  Effects of arginine on heat‐induced aggregation of concentrated protein solutions , 2011, Biotechnology progress.

[23]  Michael M C Sun,et al.  Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. , 2005, Bioconjugate chemistry.

[24]  Anna M Wu,et al.  Arming antibodies: prospects and challenges for immunoconjugates , 2005, Nature Biotechnology.

[25]  A. Bertolotti,et al.  Exposure of Hydrophobic Surfaces Initiates Aggregation of Diverse ALS-Causing Superoxide Dismutase-1 Mutants , 2010, Journal of molecular biology.

[26]  R. Ionescu,et al.  Fragmentation of monoclonal antibodies , 2011, mAbs.

[27]  W. J. Galush,et al.  Profiling antibody drug conjugate positional isomers: a system-of-equations approach. , 2012, Analytical chemistry.

[28]  A. Wahl,et al.  Secondary mAb--vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway. , 2004, Bioconjugate chemistry.

[29]  K. Imamura,et al.  On the adsorption of proteins on solid surfaces, a common but very complicated phenomenon. , 2001, Journal of bioscience and bioengineering.

[30]  Linda O Narhi,et al.  High throughput thermostability screening of monoclonal antibody formulations. , 2010, Journal of pharmaceutical sciences.

[31]  Colleen E. Price,et al.  Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. , 2008, Journal of pharmaceutical sciences.

[32]  Hanns-Christian Mahler,et al.  Protein aggregation: pathways, induction factors and analysis. , 2009, Journal of pharmaceutical sciences.

[33]  Wei Wang,et al.  Protein aggregation--pathways and influencing factors. , 2010, International journal of pharmaceutics.

[34]  Bernhardt L. Trout,et al.  Design of therapeutic proteins with enhanced stability , 2009, Proceedings of the National Academy of Sciences.

[35]  Igor V Tetko,et al.  Computing chemistry on the web. , 2005, Drug discovery today.